TSO3 Inc (fka TSTIF)

[Renee]

I haven't followed TSOS Inc. so I have no idea if 43 cents per share was a ripoff or the best that shareholders could get.

[4toSchool]

I can't believe that it ended this way. It seems that another greedy CEO grabbed a golden parachute and stiffed us common shareholders. All the while Stryker, aka big pharma, benefits handsomely from our loss. This sucks,!

[Renee]

TSTIF: Plan of Arrangement. Holders of Shares will receive, for each Share held, $0.43 in cash.

FINRA deleted symbol:

https://otce.finra.org/otce/dailyList?viewType=Deletions

[4toSchool]

I think that Stryker got a hell of a deal.

[4toSchool]

If I understand correctly the sale price is $0.325 USD per share. Is that your understanding?

[4toSchool]

Finally!!!!

[SPORT19]

Financials released today says being bought by Stryker subsidiarie for .43 CAD/ share....

[4toSchool]

No news that I've seen. But there must be something going on

[SPORT19]

All buys....someone loading the boat!!!!!

[SPORT19]

Whao! Any news out there????

[4toSchool]

This has to be a record-setting day for volume

[SPORT19]

Yup. Should have left it.
Good news today....

[4toSchool]

Strange things happen down here in pennyland

[SPORT19]

I put in a buy order for 15000 shares at .24
Never saw my order on the bid.
I canceled it...

[4toSchool]

I agree with your sentiment. I've only earned 14% and have held this stock for way too long (years).

Anyway, today was finally a day where volume and price increased. Hopefully more days like today.

GLTY

[teq0904]

Quite obviously there is nothing going on if you look for news after these so called "interesting high volume" spikes, because there is no news. \\\\\\\\\\\\\
Perhaps shift your focus to wait for news if it ever comes out instead of thinking someone buying shares has inside information and bought because he is too dumb to figure it is illegal - because the reality is they don't have any more info than anyone else and are just doing what people holding shares in 100M share companies do, which is trading stock as they see fit. ////////////////I have read 1 million posts from people who think high volume with no news means someone has been tipped off - somehow there never was any news after any of them, which means they are just like the rest of us, not insiders.

[4toSchool]

Are we seeing a trend change, or are shorts covering? I can't imagine a trader would short such a thinly traded stock, but what do I know. Some very weird and recent volume spikes.

[4toSchool]

It's interesting that high volume spikes do not significantly move the price.

[SPORT19]

Thanks..still watching this....

[4toSchool]

190k shares traded already today. Something has to be up.

[4toSchool]

Interesting trading volume today

[teq0904]

Echelon Wealth Partners update today

https://docdro.id/HWVbk1R

[SPORT19]

Thanks for the updates

[teq0904]

Today's update.. Echelon Wealth Partners

https://app.box.com/s/w1xlgcmodoewvqch7s7rxn3sxesd270b

[teq0904]

Convertible note conversion milestones :

The terms of the Convertible Note also provide for the following automatic conversion of portions of the principal amount of the Convertible Note into Common Shares at the Conversion Price when the Issuer reaches certain operational milestones which are (i) the installations in hospitals or medical clinics of at least 400 sterilizers, and (ii) annual trailing consumables revenue equivalent to at least US$10 million:

(a) 33% of the principal shall be converted when the market price of the Common Shares on the Toronto Stock Exchange (the “TSX”) calculated in accordance with the Convertible Note is at 200% or above of the Conversion Price;

(b) an additional 33% of the principal shall be converted when the market price of the Common Shares on the TSX calculated in accordance with the Convertible Note is at 250% or above of the Conversion Price; and

(c) the balance of the principal shall be converted when the market price of the Common Shares on the TSX calculated in accordance with the Convertible Note is at 300% or above of the Conversion Price.

The debt deal assumes $25k annual recurring revenue per VP4 from consumables.

[teq0904]

Analyst updates. Warning, Desjardin is a boring read.
https://www.dropbox.com/s/wwhyi2ks7c06cug/DejCourage.pdf?dl=0
http://docdro.id/Nsi1Y8c

[teq0904]

TOS financed for $20M today. Getinge is dead meat. Maybe this is for the better with all the cheap inventory buyback.

[SPORT19]

What I was getting at is that sterile is always better than disinfected.
Thanks for posting!

[teq0904]

The problem is the patients don't know about it, and the unions don't like this product because it puts their brothers out of work. Lots of hospitals let a processor's union member make the decision to purchase this equipment because they don't realize there is a conflict of interest.

[SPORT19]

Great update! Thanks for posting.
If you were a patient and had a choice between a STERILE scope or a scope with HLD which would you want?

[teq0904]

RE:AAMI ST/WG84
I was unable to take in all of the meeting of WG84, but here are my take aways from the morning of 19th and some of afternoon:


1) AAMI committee members fought off a proposed change the draft of the standard that used wording trying to assert that scopes passing through dirty cavity like mouth or bowel don’t need to be sterilized because having passed through a nonsterile cavity they could no longer be considered sterile when they are used to enter a sterile cavity (such as to do a biopsy). The group soundly rejected this revision and discussed that the point of all of this WG84 work since the FDA meeting in early 2015 is that duodenoscopes and other endoscopes do need to be sterilized because of cross contamination between patients (and the issue is not contamination from the patient themselves). This attempted revision also listed a group of scopes that specifically mentioned all relevant endoscopes but not duodenoscopes. This attempt to exclude duodenoscopes was soundly rejected and the list itself removed and reference was left to only all endoscopes needing to be terminally sterilized.


2) It was felt no date should yet be published by which implementation of low temperature sterilization adoption by a hospital or GI suite must necessarily be completed, though they recommended wording stating sterilization is recommended when possible for the whole list of endoscopes. This is very important! Not establishing a date like mid 2019 or 2020 for adoption by all does not mean that the new standards do not recommend terminal sterilzation as soon as possible, it simply recognizes that the group cannot take on establishing a date for practical reasons. Will TSO3 be able to meet demand of not only 1500 low temperature sterilizers per year to replace existing sterilizers that are old and failing, but what of the entire installed base of 20,000+ units in NA alone that will need to be upgraded over the next few years to this new technology standard and provide the best patient care? The group recognized in their comments that these recommendations will definitely cause a dramatic shift in practice and standard of care with implications for all involved, (including legal liabilities for those who do not yet have a VP4 sterilizer if and when patients become il or die due to being exposed to contaminated duodenoscopes, complex gastroscopes, or colonoscopes for example- with the VP4 being the only LTS system that is effective and recognized by the FDA to terminally sterilize this huge swath of endoscopes).


3) The point was reiterated that HLD has been repeatedly found in independent studies NOT to be effective in eliminating bacterial contamination for many endoscopes including duodenoscopes and that only terminal sterilization does this. (It was not discussed that ETO has also been shown also to be ineffective as a method of terminal sterilzation of duodenoscopes among other scopes, but the group appeared to be referring to TSO3's VP4 as THE terminal low temperature sterilization solution and they spent about 40 minutes discussing wording and housekeeping regarding references to TSO3's H2O2 and Ozone technology alone.)

4) The group also discussed again and accepted (over Olympus’s comment and half-hearted objection) that IFU’s are to be accepted if done by scope OEM or sterilizer manufacturer. This latter has now gone through second draft and is extremely positive. Olympus did not object and supports the wording! Again, this accepts a total shift in practice re: FDA and IFU’s that will allow TOS to do their own IFU’s and that these will meet standard of FDA.... all excellent!

5) Olympus did request that it be recognized that terminal sterilization results in more wear and tear for scopes over HLD but the comment was rejected as Olympus has no actual data to support this contention, recognizing the FDA is looking into and studying this, (in consultation with TSO3). This is for further study and is to be part of Olympus’s internal risk assessment but not part of the WG84 standard of care recommendations. This rejection which was politely accepted by the Olympus rep is also extremely positive for TSO3, with group reiterating emphasis on doing more preventative maintenance and the group again emphasizing the need to inspect scopes routinely between uses.

6) A revision was also soundly rejected that might have claimed that terminal sterilzation was impractical and inefficient due to time but the group rejected that terminal sterilation with new technology (=VP4) takes significantly longer than HLD. It was noted that with H2O2 + Ozone technology HLD is not required as part of the reprocessing protocol and that the cycle time was in the range of only an hour. A busy endoscopy clinic might need to add one or two duodenscopes to maintain their high volume and turnover, but this was reasonable and certainly not prohibitive to improving the quality of care for patients. Washing protocols were of course discussed as essential prior to terminal sterilization as is the new standard of 10 minutes of drying time after washing before putting the endoscope through the sterilizer.

IMHO.... this is exactly what TOS had hoped for with this latest draft revision. The VP4 remains a market disruptive techology! With the team from TSO3 at table, all went extremely well!! I would anticipate a final draft might be prepared for the fall AAMI Standards Meeting.

The market has seriously mispriced TOS in light of the value of this technology. But, investors have definitely lost confidence in management's ability to deliver on expectations and take over this LTS market. However, I strongly expect that the next few days and weeks will bring news that will substantially surprise on the upside in terms of the VP4 getting market traction (both in terms of Getinge sales recently and TSO3 orders) following FDA extended unique claims for the Olympus duodenoscope and the growing positive user experience. Again, IMHO, RR will never do an equity financing at any share price level remotely near where we are today and he won't need to. Why would they not simply get a LOC for a 3-5 year term from a bank or Caisse at a reasonable interest rate that would remove the prospect of a financing completely and reassure the market? If sales take off, as I suspect they are and will be in light of FDA news, strategic installs and excellent cost efficiencies to users being reported by early adopters, etc., TSO3 would not even need to use much or any of a Line of Credit financial cushion over the next year to continue growing independently as well as working with Getinge (and others possibly in markets where Getinge is not active) under similar arrangements to the one that exists now. This share price remains ludicrous.

[teq0904]

Also on Stockhouse, dr wong who hasn't posted for a few weeks is a former analyst. He did a calculation that tos shares are worth $90 but it was early in 2018 and would be a lot of digging to find it. He has a detailed spreadsheet with cash flow projections and said he has never put so much time into a stock so was quite serious.

[teq0904]

TOS got FDA approval for duodenoscopes a few months ago. The Altrus hospital in ND has been the first to use it for this purpose.

[SPORT19]

Thanks

[teq0904]

You can get better info if you post your question here (then post whatever info you get back on ihub) because echo, and DrWong are surgeons or work in the area and have huge positions in TOS so I rely on them. They are in constant contact with Rick Rumble to the point of being anal.
http://www.stockhouse.com/companies/bullboard/t.tos/tso3-inc

There is another guy, bossu, who does a car count of the factory parking lot so we actually have a good idea of what the deliveries are. That is his sole value.

[SPORT19]

While I don't have the statistics I would imagine that the majority of endoscopy cases are done at ambulatory care facilities.
I'm a surgical tech with 25 years OR experience.

[teq0904]

The analysts downplay the duo approval and use silly conservative estimates like late in 2018 for approval, when the reality is this next submission is just more of the same kind of data showing scopes are not damaged using TOS device - they sent this before and FDA already accepted but wants more examples.

https://app.box.com/s/yhi6n1ozxxqjpke53j40xiyyv5653ktq

About the only interesting report is Scotia with 2 user testimonials and TSO3 calculation that every sale is worth $1M over the lifetime of the device. 3,000 sterilizers wear out every year although that includes the OR size which TOS doesn’t have at present but will at some point. Or consider there are 30k sterilizers out there and will be more once TOS gets FDA approval for the duodenoscope because every US hospital will need one.
Echelon said the list of US hospitals sued over disinfected duodenoscopes that resulted in infections and deaths is long and growing. No matter how tiny TOS sales force is, if US hospitals want an insurance policy against $4M lawsuits that costs nothing (opex savings will cover the capital costs over time) then they will gladly install a VP4 and junk their disinfection washer systems – at that point, even unmotivated Getinge salesmen will be able to make this easy sale.

[SPORT19]

Thank you for the updates and the insight.

[teq0904]

Normally, there is no way why the stock didn't react positively to that presentation and PR, unless the overall market is really tanking (which is not the case). But now I am pretty comfortable that I know why.
However, we will have to endure more of this selling pressure as Sprott still has a lot to let go.

[teq0904]

I am sure many of you will say: "but the stock price is tanking, doesn't it tell you something?" It would normally, but I have a theory on why the selling pressure has picked up in the last few days, so please hear me out.

When we look at the top holders list, we know Sprott Cdn Equity Fund owns about 3.6mm shares, or 4%. They recently (Feb15) let go of their portfolio managers of that Fund due to performance. These outgoing managers are big believers of TSO3, and put >10% of the Fund in it.

Link: https://globenewswire.com/news-release/2018/02/15/1349202/0/en/Ninepoint-Partners-LP-Announces-Changes-to-Portfolio-Manager-Line-Up.html

The Fund is put into temporary custody under another manager at Ninepoint, but the Fund will be merged into the Sprott Concentraed Cdn Equity Fund by the end of March. That fund is outsourced to Scheer, Rowlett & Associates. If you look at Scheer's other Cdn Equity Fund, you can see their focus is on large cap value names. At the very least, they do not want a 10% position in TSO3 like it was at the old Sprott fund.

Link: https://www.cclgroup.com/cclfunds/en/home/our-strategies/separately-managed-account-strategies/scheer-rowlett-canadian-equity/overview

As a result, I don't think they will want to keep the TSO3 position (or sell a big chunk of it at the very least). I have seen several of these fund mergers in my career, and the new incoming managers will actually direct the interim custodian manager of what to do during the transition--to get the portfolio into something they want, and they are price insensitive. Reason--performance is not attributed to the new manager during this transition period, only when they officially take over the fund. Furthermore, trading desks of major brokers will sometimes look at the portfolios of these transitioning funds and trade against them, if they are pretty sure the new portfolio managers will need to liquidate certain illiquid positions, like a TSO3. On the flipside, existing or potentially new shareholders could come in to clean up these blocks. But they typically want a "deal" on price.

[teq0904]

After listening to the RBC presentation and reading the Getinge PR recently, I doubt anyone could say the business fundamentals of TSO3 is worse now vs. when the preception on Jan25 when the interim deal PR came out:
- Getinge relationship sounds more solid: RR explained that TSO3 is only marketing to hospitals not targeted by Getinge, and the very complimentary Getinge PR showed us the working relationship is sound and low temperature sterilization is a key strategic market for them
- We also got more evidence of how VP4 performs in real life, and how it is truly a next-gen product: ability to do scopes, lower costs through higher load/throughput/mix load, lower operator mistakes. The robotic arm piece of news is significant as well
- FDA: now everyone knows sterility is never an issue, but compatibility. It all comes down to what the labeling will look like, and how often hospitals will need to inspect their scopes. For me, this is a matter of when, not if.

[teq0904]

Ten days ago, the FDA acknowledged having received the application for the extended version of the VP4 . After having done a first survey of conformity with the rules and requirements, it is now ready to take on the analytical part of the study. Starting yesterday, the staff has had to make sure they do not own shares of Tso3 (it's a common procedure).

Last year, it took them barely five weeks to isssue a 510(k) to TSO3.

[4toSchool]

IIROC Trade Resumption - TOS

[4toSchool]

TSO3 and Global Distributor Agree on Co-Commercial Strategy for North America Thursday, January 25, 2018

Quebec City, Canada and Myrtle Beach, United States, January 25, 2018 – TSO3 Inc. (TSX: TOS), (“TSO3” or the “Company”), an innovator in sterilization technology for medical devices in healthcare settings, announced today that, in a joint effort to increase sales to end users and optimize the customer experience, it has entered into a new agreement (the “Sales and Repurchase Agreement”) with Getinge Infection Control AB, its global distribution partner. The Sales and Repurchase Agreement allows the Company to sell its STERIZONE® VP4 Sterilizers and associated products and services directly into the United States and Canada and repurchase not less than 100 STERIZONE® VP4 sterilizers for $3.3 million, with an initial order of 30 units. Getinge will continue to sell its inventory in North America and the rest of the world and the parties have agreed to a customer selection mechanism to prevent the likelihood of channel conflict.

“Our relationship with Getinge has evolved over the past two years, and we believe these modifications to our relationship will add speed and flexibility to our joint sales and marketing efforts, while addressing inventory levels,” stated R.M. (Ric) Rumble, President and CEO of TSO3. “We look forward to continuing to support Getinge, and driving additional business while providing optimal support to all TSO3 customers.”

The Parties have also agreed to begin immediate negotiations on additional modifications to the distribution relationship with the objective of further increasing the speed, flexibility and effectiveness of the relationship. The Sales and Repurchase Agreement and the Exclusive Distribution Agreement signed between the Parties on November 25, 2015, will terminate on August 1, 2018 unless extended by mutual agreement. If agreement between the parties is not reached, TSO3 has agreed, by July 1, 2019, to repurchase Getinge’s remaining STERIZONE® VP4 Sterilizers at the same unit price in the Sales and Repurchase Agreement.

The Company is redirecting some of its internal resources toward sales and marketing, and has nearly completed the build out of the Company’s team of experienced sales, clinical and field service professionals. These professionals are now immediately tasked with selling and providing support directly to end users in the central sterilization (CSSD) department of acute care hospitals, as well as to develop additional opportunities in the gastrointestinal reprocessing market segment. Based on customer feedback the Company has received, the Company is already able to provide sales and customer support at industry leading levels. TSO3 will continue to support Getinge in the sale, support, installation and servicing of existing and future customers.

About the STERIZONE® VP4 Sterilizer

The STERIZONE® VP4 Sterilizer is a low-temperature sterilization system that utilizes the dual-sterilants of vaporized hydrogen peroxide (H2O2) and ozone (O3) to achieve terminal sterilization of heat and moisture sensitive medical devices. Its single pre-programmed cycle can sterilize a large number and wide range of compatible devices, creating a cost-effective sterilization process with error free cycle selection. The device's unique Dynamic Sterilant Delivery System™ automatically adjusts the quantity of injected sterilant based on the load composition, weight and temperature. This capability removes the guesswork and potential for human error, as there is no need to sort instruments and choose the appropriate cycles as with other machines.

The STERIZONE® VP4 Sterilizer is the only terminal sterilization method that is FDA cleared to sterilize multi-channeled flexible endoscopes (with a maximum of four channels) of up to 3.5 meters in length, such as video colonoscopes and gastroscopes - an industry first for any medical device sterilization process.

The STERIZONE® VP4 Sterilizer is also the only cleared low temperature sterilizer that can process a mixed load consisting of general instruments, single channel flexible endoscopes, and single or double channel rigid endoscopes in the same cycle with load weights of up to 75 lb. The ability to run mixed loads significantly reduces labor costs by minimizing the amount of instrument sorting required, while maximizing the device turns (more productivity from increased throughput capacity).

More information about the STERIZONE® VP4 Sterilizer is available through TSO3's website, under the Products section at http://www.tso3.com/en/products/sterizone-vp4/.

[4toSchool]

PENDING NEWS: IROC Trade Halt - TSO3 Inc.

Company: TSO3 Inc.
TSX Symbol: TOS (all issues)
Reason: Pending News
Halt Time (ET) 09:42

IIROC can make a decision to impose a temporary suspension of trading in a security of a publicly listed company, usually in anticipation of a material news announcement by the company. Trading halts are issued based on the principle that all investors should have the same timely access to important company information. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

[4toSchool]

Hi Sport. Welcome to the board.

My story: My wife is a nurse at our local hospital. After hearing of the equipment that is thrown out because of the inability to sterilize at high temperatures I thought that TSO3 and their low temperature sterilization offering was headed for huge success. That was about 15 years ago.

About 18-months ago I sold 1/2 of my position at $2.65. Fortunately I do see the stock gaining traction so far this year. It might just be heading back up.

I've always hoped, especially after their FDA approval, that some billion dollar medical corp would buy them out.

I have to admit that I've not kept up on all the due diligence of this investment. I hope that this board might get active and we can share good info with each other. I really think that something is happening behind the scenes, or it could be all those taking advantage of 2017 tax write-offs getting back into the stock. I hope that it is mainly the former driving the recent pps increase.

GLTY

[SPORT19]

Looking to start a position here. I'm a Surgical Technologist and believe these sterilization units have huge potential.

[4toSchool]

TSO3 Duodenoscope Sterilization Technology to be Featured at the 18th World Federation for Hospital Sterilisation Sciences (WFHSS) Congress in Bonn, Germany
QUEBEC CITY and MYRTLE BEACH, SC, Oct. 3, 2017 /PRNewswire/ - TSO3 Inc. (TSX: TOS), an innovator in sterilization technology for medical devices in healthcare settings, today announced that Mr. Albert Csapo, BA, Manager, Medical Device Reprocessing Department, Vancouver General Hospital (VGH), the University of British Columbia Hospital (UBCH), and satellites at GLDHCC, ECC, and Endoscopy, shall give a presentation titled "Sterilization of endoscopes and why we chose a low-temperature reprocessing method" on Friday, October 6th during the 18th WFHSS Congress in Bonn, Germany.

Mr. Csapo's presentation will discuss VGH's use of the STERIZONE® VP4 Sterilizer to sterilize duodenoscopes used in Endoscopic Retrograde Cholangiopancreatography (ERCP) procedures and how they have successfully transitioned to full terminal sterilization of their duodenoscopes.

"Since 2009, the reprocessing of endoscopes and the possibility of the transmission of bacterium from patient to patient due to the difficulty in cleaning these scopes have been well documented throughout North America and Europe", stated Mr. Csapo, "The complex design of duodenoscopes used in Endoscopic Retrograde Cholangiopancreatography (ERCP) have been linked to numerous outbreaks of the deadly bacteria Carbapenem-Resistant Enterobacteriaceae (CRE) in numerous healthcare facilities. Out of an abundance of caution, Vancouver General Hospital decided to move to low-temperature sterilization of ERCP scopes and to evaluate an exciting new technology that would allow this level of reprocessing at sites throughout the province of British Columbia."

"We are delighted with the progress made at VGH" stated R.M. (Ric) Rumble, President and CEO of TSO3. "Through systematic testing and documentation, we are generating real world evidence that demonstrates that the terminal sterilization of duodenoscopes is not only possible but practical."

TSO3 expects to make Mr. Csapo's presentation available on its website at www.tso3.com on Friday, October 6, 2017.

About the STERIZONE® VP4 Sterilizer

The STERIZONE® VP4 Sterilizer is a low-temperature sterilization system that utilizes the dual-sterilants of vaporized hydrogen peroxide (H2O2) and ozone (O3) to achieve terminal sterilization of heat and moisture sensitive medical devices. Its single pre-programmed cycle can sterilize a large number and wide range of compatible devices, creating a cost-effective sterilization process with error free cycle selection. The device's unique Dynamic Sterilant Delivery System™ automatically adjusts the quantity of injected sterilant based on the load composition, weight, and temperature. This capability removes the guesswork and potential for human error, as there is no need to sort instruments and choose the appropriate cycles as with other machines.

The STERIZONE® VP4 Sterilizer is the only terminal sterilization method that is FDA cleared to sterilize multi-channeled flexible endoscopes (with a maximum of four channels) of up to 3.5 meters in length, such as video colonoscopes and gastroscopes - an industry first for any medical device sterilization process.

The STERIZONE® VP4 Sterilizer is also the only cleared low-temperature sterilizer that can process a mixed load consisting of general instruments, single-channel flexible endoscopes, and single or double channel rigid endoscopes in the same cycle with load weights of up to 75 lb. The ability to run mixed loads significantly reduces labor costs by minimizing the amount of instrument sorting required, while maximizing the device turns (more productivity from increased throughput capacity). More information about the STERIZONE® VP4 Sterilizer is available through TSO3's website, under the Products section at http://www.tso3.com/en/products/sterizone-vp4/.

About TSO3

Founded in 1998, TSO3's activities encompass the sale, production, maintenance, research, development and licensing of sterilization processes, related consumable supplies and accessories for heat-sensitive medical devices. The Company designs products for sterile processing areas in the hospital environment that offer an advantageous replacement solution to other low-temperature sterilization processes currently used in hospitals. TSO3 also offers services related to the maintenance of sterilization equipment and compatibility testing of medical devices with such processes.

For more information about TSO3, visit the Company's website at www.tso3.com.

The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of TSO3's regulatory filings, revenue, business or operations) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, the ability of the Company to obtain the required regulatory clearances to market its products, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties. Although TSO3 believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. The complete versions of the cautionary note regarding forward-looking statements as well as a description of the relevant assumptions and risk factors likely to affect TSO3's actual or projected results are included in the Management's Discussion and Analysis for the year ended December 31, 2016, which is available on the Company's website. The forward-looking statements contained in this press release are made as of the date hereof, and TSO3 does not assume any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise unless expressly required by applicable securities laws.



SOURCE TSO3 Inc.

[4toSchool]

Congratulations, you made some good purchases.

I've been in $TSTIF for too long. I was hoping for a buyout after they received FDA approval many years ago. I sold 1/2 my position at $2.65, which was my best move on this stock.

I like your $5 price target. Let's hope for some profits or a buyout.

$TSTIF

[rtt]

Picked some up at 50 cents, more at $1. Sold some off, but waiting to see if they can actually make money instead of losing it. If they do show a profit I expect it will go to about $5.